Slide 1: Multicenter Phase II Trial Of LN-145 TIL Cell Therapy Plus Pembrolizumab in ICI-Naïve Metastatic NSCLC
Multicenter Phase II Trial Of LN-145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI-Naïve Metastatic NSCLC Adam Schoenfeld1; Kai He2; Jason Chesney3; Edward Garon4; Jorge Nieva5; Adrian Sacher6; Sylvia Lee7; Friedrich Graf Finckenstein8; Rana Fiaz8; Melissa Catlett8; Guang Chen8; Viktoria
Slide 2: IOV-COM-202 3A: LN-145 + anti–PD-1 in ICI-naïve mNSCLC
IOV-COM-202 3A: LN-145 + anti–PD-1 in ICI-naïve mNSCLC Merging Potent Immunotherapy Modalities Introduction Methods and Objective • Benefit from front-line ICI ± chemotherapy in patients with • IOV-COM-202 (NCT03645928) is a global, phase 2, multicenter, multicohort mNSCLC is limited by primary and
Slide 3: Results: Baseline Demographics and Safety Data
Results: Baseline Demographics and Safety Data Majority of Patients Were PD-L1–Negative With High Disease Burden Table 1. Baseline Patient and Disease Characteristics Table 2. Non-hematologic TEAEs in ≥30% of Patientsj Table 3. Grade 3/4 Hematologic Lab Characteristics Cohort 3A (N=19) Cohort 3A (N=
Slide 4: Results: Clinical Efficacy in ICI-naïve mNSCLC
Results: Clinical Efficacy in ICI-naïve mNSCLC Responses (RECIST v1.1) Observed Independent of PD-L1 Status Figure 2. Best Percentage Change from Baseline in Target Lesion SOD for Evaluable Patients Table 4. Best Overall Response 100 Best Overall Cohort 3A (N=19) Treatment-naïve Post-chemotherapy EG
Slide 5: Results: Clinical Efficacy – Durable Responses Were Observed
Results: Clinical Efficacy in ICI-naïve mNSCLC Durable Responses Were Observed Figure 3. Time to Response and Time on Efficacy Assessment for Confirmed Responders (PR or Better) Figure 4. Percentage Change from Baseline in Target Lesion SOD 80 PD-L1 BOR on 3A-03 (PD) Subgroup Pt TPS (%)a Mutation St
Slide 6: Infused TCR Clonotypes Over Time and Cell Dose
Infused TCR Clonotypes Over Time and Cell Dose Infused TIL Persist in Peripheral Blood and Cell Dose Did Not Differ By Response Figure 5. Persistence of Infused TIL* Figure 6. Total Cell Dose 80 p = 0.6567 Responder % TCR Repertoire 100 Nonresponder 60 Total Dose (billions) 50 40 0 Pre-Infusion Day
Slide 7: Trial Conclusions
Trial Conclusions TIL Cell Therapy Activity May Be Independent of PD-L1 Status in ICI-naïve mNSCLC • In patients with ICI-naïve mNSCLC, activity of LN-145 plus pembrolizumab was greater than what has previously been reported for LN‐145 monotherapy or pembrolizumab alone and was not limited by PD-L1